Drug Profile
Dendritic cell-activated cytotoxic T lymphocytes cells - Shenzhen Hornetcorn Biotechnology
Alternative Names: DC activated CTL - Shenzhen Hornetcorn Biotechnology; DC-CTL - Shenzhen Hornetcorn Biotechnology; Dendritic cell cytotoxic T lymphocyte cell therapy - Shenzhen Hornetcorn BiotechnologyLatest Information Update: 28 Jun 2019
Price :
$50
*
At a glance
- Originator Shenzhen Hornetcorn Biotechnology
- Class Antineoplastics; Cell therapies; Dendritic cell vaccines; Immunotherapies
- Mechanism of Action Immunostimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported Non-small cell lung cancer
Most Recent Events
- 28 Jun 2019 No recent reports of development identified for clinical-Phase-Unknown development in Non-small-cell-lung-cancer in China (IV, Infusion)
- 06 May 2016 Shenzhen Hornetcorn Bio-technology Company plans a phase II trial for Non-small cell lung cancer (Late-stage disease, Combination therapy) in China (IV) (NCT02766348)
- 05 May 2016 Clinical trials in Non-small cell lung cancer in China (IV) before May 2016